Non-canonical ERAD as a Regulator of Cardiac Hypertrophy

非典型 ERAD 作为心脏肥大的调节剂

基本信息

  • 批准号:
    10363838
  • 负责人:
  • 金额:
    $ 61.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-01 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Increases in protein synthesis during pathological cardiac hypertrophy places demands on protein-folding machinery to avert the accumulation of toxic misfolded proteins. Associated with the endoplasmic reticulum (ER), where many important proteins are synthesized in cardiac myocytes, is a system that recognizes and degrades misfolded proteins, i.e. ER associated (protein) degradation, or ERAD. We discovered a different, non-canonical role for ERAD as a regulator of the levels of the growth-promoting kinase, serum glucocorticoid kinase 1 (SGK1). SGK1 is a cytosolic kinase involved in growth of other cell types, such as cancer cells. Interestingly, SGK1 can traffic to the ER where it is ubiquitylated by ERAD machinery and subsequently degraded by cytosolic proteasomes; however, this unique regulatory mechanism has not been studied in the heart. Our preliminary evidence shows that non-canonical ERAD could regulate SGK1 levels in the heart and, thereby regulating cardiac growth under pathological conditions. We also found that an SGK1-binding protein, called glucocorticoid-inducible leucine zipper protein (GILZ), can bind to and protect SGK1 from non-canonical ERAD-mediated degradation, which we believe increases SGK1-mediated growth of the heart during pressure overload. Accordingly, our hypothesis is that SGK1 is a major inducer of pressure overload-induced cardiac pathology. During pressure overload, SGK1 levels, and thus, SGK1-mediated cardiac hypertrophy and subsequent pathology, are increased by GILZ-dependent diversion of SGK1 away from the ER, which decreases SGK1 degradation by non-canonical ERAD. Ectopic expression of an SGK1 peptide disrupts the GILZ-SGK1 interaction, increases SGK1 degradation, thus decreasing SGK1-mediated cardiac hypertrophy and subsequent pathology. This hypothesis will be examined in mice subjected to pressure overload-induced cardiac pathology in our specific aims, which are to 1-couple cardiac-specific SGK1 deletion with AAV9 encoding SGK1-WT (active; ER-targeted), SGK1-KD (kinase-dead ER-targeted) or SGK1-∆60 (active; not ER-targeted) to examine the effect of SGK1 and ERAD on overload-induced cardiac pathology, 2-combine AAV9-SGK1-WT or AAV9- SGK1-∆60 with AAV9-mediated GILZ overexpression or knockdown to determine whether GILZ diverts SGK1- WT from the ER and protects it from ERAD in the heart, 3-evaluate the potential therapeutic, antihypertrophic effects of a novel SGK1 peptide that interrupts GILZ-SGK1 binding, and increases non-canonical ERAD- mediated SGK1 degradation. These studies are significant because they will reveal previously unappreciated roles for SGK1, GILZ and ERAD in pathologic cardiac hypertrophy. We will use an innovative molecular strategy to mechanistically dissect roles for GILZ and non-canonical ERAD as regulators of SGK1 signaling and cardiac pathology. Peptide-based disruption of the SGK1-GILZ interaction could be a highly specific method for inhibiting the maladaptive pathological effects of SGK1 in the heart by selective degradation of SGK1.
项目摘要 病理性心肌肥大过程中蛋白质合成的增加对蛋白质折叠提出了要求 避免有毒错误折叠蛋白质积累的机制。与内质网有关 (ER)在心肌细胞中合成许多重要蛋白质的系统,是一种识别和 降解错误折叠的蛋白质,即ER相关的(蛋白质)降解,或ERAD。我们发现了一种不同的, ERAD作为促生长激酶、血清糖皮质激素水平调节剂的非典型作用 激酶1(SGK 1)。SGK 1是一种参与其他细胞类型(如癌细胞)生长的胞质激酶。 有趣的是,SGK 1可以运输到ER,在ER中它被ERAD机制泛素化, 被胞质蛋白酶体降解;然而,这种独特的调节机制尚未在 心我们的初步证据表明,非经典ERAD可以调节心脏中的SGK 1水平, 从而调节病理条件下的心脏生长。我们还发现了SGK 1结合蛋白, 称为糖皮质激素诱导的亮氨酸拉链蛋白(GILZ),可以结合并保护SGK 1免受非典型的 ERAD介导的降解,我们认为在压力下增加了SGK 1介导的心脏生长 超载。因此,我们的假设是SGK 1是压力超负荷诱导的心脏损害的主要诱导物。 病理在压力超负荷期间,SGK 1水平,因此,SGK 1介导的心肌肥大和 GILZ依赖性SGK 1从ER转移,从而降低了随后的病理学, 非典型ERAD引起的SGK 1降解。SGK 1肽的异位表达破坏GILZ-SGK 1 相互作用,增加SGK 1降解,从而减少SGK 1介导的心脏肥大和随后的 病理这一假设将在压力超负荷诱导的心脏病理学小鼠中进行检验 在我们的具体目标中,其是将心脏特异性SGK 1缺失与编码SGK 1-WT的AAV 9 1-偶联 (活性; ER靶向)、SGK 1-KD(激酶死亡ER靶向)或SGK 1-KD 60(活性;非ER靶向)进行检查 SGK 1和ERAD对超负荷诱导心脏病理学的影响,2-联合收割机AAV 9-SGK 1-WT或AAV 9- 用AAV 9介导的GILZ过表达或敲低SGK 1-SGK 60,以确定GILZ是否转移SGK 1-SGK 60。 WT从ER和保护它从ERAD在心脏,3-评估潜在的治疗,抗肥大 一种新的SGK 1肽的作用,中断GILZ-SGK 1结合,并增加非经典ERAD- 介导的SGK 1降解。这些研究意义重大,因为它们将揭示以前未被重视的 SGK 1、GILZ和ERAD在病理性心脏肥大中的作用。我们将使用创新的分子策略 从机制上剖析GILZ和非经典ERAD作为SGK 1信号传导和心脏信号传导调节因子的作用, 病理基于肽的SGK 1-GILZ相互作用的破坏可能是抑制GILZ的高度特异性方法。 通过选择性降解SGK 1,SGK 1在心脏中的适应不良病理效应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chris Glembotski其他文献

Chris Glembotski的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chris Glembotski', 18)}}的其他基金

Non-canonical ERAD as a Regulator of Cardiac Hypertrophy
非典型 ERAD 作为心脏肥大的调节剂
  • 批准号:
    10544178
  • 财政年份:
    2022
  • 资助金额:
    $ 61.5万
  • 项目类别:
Non-canonical ERAD as a Regulator of Cardiac Hypertrophy
非典型 ERAD 作为心脏肥大的调节剂
  • 批准号:
    10817347
  • 财政年份:
    2022
  • 资助金额:
    $ 61.5万
  • 项目类别:
The ER Stress-Induced Selenoprotein, SelenoS, Regulates Proteostasis and Cardiac Hypertrophy
内质网应激诱导的硒蛋白 SelenoS 可调节蛋白质稳态和心脏肥大
  • 批准号:
    10550149
  • 财政年份:
    2020
  • 资助金额:
    $ 61.5万
  • 项目类别:
Harnessing the Adaptive ER Stress Response in Myocardial Ischemia
利用适应性 ER 应激反应治疗心肌缺血
  • 批准号:
    10227351
  • 财政年份:
    2020
  • 资助金额:
    $ 61.5万
  • 项目类别:
The ER Stress-Induced Selenoprotein, SelenoS, Regulates Proteostasis and Cardiac Hypertrophy
内质网应激诱导的硒蛋白 SelenoS 可调节蛋白质稳态和心脏肥大
  • 批准号:
    10322459
  • 财政年份:
    2020
  • 资助金额:
    $ 61.5万
  • 项目类别:
The ER Stress-Induced Selenoprotein, SelenoS, Regulates Proteostasis and Cardiac Hypertrophy
内质网应激诱导的硒蛋白 SelenoS 可调节蛋白质稳态和心脏肥大
  • 批准号:
    10218914
  • 财政年份:
    2020
  • 资助金额:
    $ 61.5万
  • 项目类别:
ATF6 is Required for ANP Secretion from the Heart
ATF6 是心脏分泌 ANP 所必需的
  • 批准号:
    10219762
  • 财政年份:
    2018
  • 资助金额:
    $ 61.5万
  • 项目类别:
Harnessing the Adaptive ER Stress Response in Myocardial Ischemia
利用适应性 ER 应激反应治疗心肌缺血
  • 批准号:
    9389978
  • 财政年份:
    2017
  • 资助金额:
    $ 61.5万
  • 项目类别:
Harnessing the Adaptive ER Stress Response in Myocardial Ischemia
利用适应性 ER 应激反应治疗心肌缺血
  • 批准号:
    9924642
  • 财政年份:
    2017
  • 资助金额:
    $ 61.5万
  • 项目类别:
Role of the SR/ER E3 Ubiquitin Ligase Synoviolin 1 in Cardiac Hypertrophy
SR/ER E3 泛素连接酶 Synoviolin 1 在心脏肥大中的作用
  • 批准号:
    9102175
  • 财政年份:
    2015
  • 资助金额:
    $ 61.5万
  • 项目类别:

相似海外基金

In vivo and ex vivo lessons from somatic adrenal mutations in cell adhesion molecule 1 for physiological and pathological production of aldosterone
细胞粘附分子 1 体细胞肾上腺突变对醛固酮生理和病理产生的体内和离体教训
  • 批准号:
    MR/X018970/1
  • 财政年份:
    2023
  • 资助金额:
    $ 61.5万
  • 项目类别:
    Fellowship
Creating therapeutic strategies targeting both aldosterone and AGEs-RAGE axis for stopping kidney diseases progression
制定针对醛固酮和 AGEs-RAGE 轴的治疗策略,以阻止肾脏疾病的进展
  • 批准号:
    23K15240
  • 财政年份:
    2023
  • 资助金额:
    $ 61.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Processivity and Catalytic Mechanism of Aldosterone Synthase
醛固酮合酶的持续合成能力和催化机制
  • 批准号:
    10600520
  • 财政年份:
    2023
  • 资助金额:
    $ 61.5万
  • 项目类别:
Aldosterone/mineralocorticoid receptor responses to biologic sex and salt intake: Role of Lysine Specific Demethylase 1 (LSD1)
醛固酮/盐皮质激素受体对生物性别和盐摄入量的反应:赖氨酸特异性脱甲基酶 1 (LSD1) 的作用
  • 批准号:
    10930190
  • 财政年份:
    2023
  • 资助金额:
    $ 61.5万
  • 项目类别:
Development of a CYP11B2 probe for imaging aldosterone-producing adenomas with high sensitivity.
开发用于高灵敏度对产生醛固酮的腺瘤进行成像的 CYP11B2 探针。
  • 批准号:
    23H02850
  • 财政年份:
    2023
  • 资助金额:
    $ 61.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Aldosterone blockade for Health Improvement Evaluation in End-stage kidney disease: Extension
醛固酮阻断用于终末期肾病健康改善评估:延伸
  • 批准号:
    461992
  • 财政年份:
    2022
  • 资助金额:
    $ 61.5万
  • 项目类别:
    Operating Grants
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
利钠肽-肾素-血管紧张素-醛固酮系统节律轴与夜间血压
  • 批准号:
    10545747
  • 财政年份:
    2022
  • 资助金额:
    $ 61.5万
  • 项目类别:
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
利钠肽-肾素-血管紧张素-醛固酮系统节律轴与夜间血压
  • 批准号:
    10342142
  • 财政年份:
    2022
  • 资助金额:
    $ 61.5万
  • 项目类别:
Role of Renin-Angiotensin-Aldosterone System during sarcoidosis granuloma formation
肾素-血管紧张素-醛固酮系统在结节病肉芽肿形成过程中的作用
  • 批准号:
    10591934
  • 财政年份:
    2022
  • 资助金额:
    $ 61.5万
  • 项目类别:
Association between excessive salt intake and brain renin-angiotensin-aldosterone system in obesity.
肥胖中过量盐摄入与脑肾素-血管紧张素-醛固酮系统之间的关联。
  • 批准号:
    22K08167
  • 财政年份:
    2022
  • 资助金额:
    $ 61.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了